Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07096024 · ClinicalTrials.gov registry record
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
A clinical trial of Breast Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- 1,772
- Enrollment target
- 1
- Study location
NCT07096024: Completed study of Breast Neoplasms, sponsored by Pfizer.
NCT07096024 is a study of Breast Neoplasms that has completed, run by Pfizer. The registered enrollment target is 1,772 participants, above the 551-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (222% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07096024, a study of Breast Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1,772 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to: * compare the chances of getting interstitial lung disease (ILD) in new users of palbociclib plus fulvestrant to new users of fulvestrant alone (using data from before palbociclib was out in the market) * look into the factors that can cause ILD in new users of palbociclib. This study uses patient data without giving out any personal information of the patient. This data is taken from a hospital-based claims database of the MDV database, that includes data from more than 400 hospitals in Japan. This study will use data of patients who are: * diagnosed with breast cancer that include newly treated with palbociclib and/or other endocrine-based therapies for inoperable or recurrent breast cancer between 25 November 2011 and 30 November 2024.
Conditions Studied
Interventions
- DRUG fulvestrant
- DRUG palbociclib plus fulvestrant
Study Locations (1)
New York
- Pfizer New York - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,772 participants |
| Start Date | 2025-01-21 |
| Est. Completion | 2025-02-07 |
What the finished NCT07096024 record still lists
NCT07096024 is an observational study that tracks outcomes without assigning an intervention. Its 1,772 participants enrollment target places it among the larger protocols in the corpus, above the 551-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (222% higher).
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which fulvestrant is the first listed.
NCT07096024 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07096024 about?
NCT07096024 is a clinical study titled "A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market". The purpose of the study is to: * compare the chances of getting interstitial lung disease (ILD) in new users of palbociclib plus fulvestrant to new users of fulvestrant alone (using data from before palbociclib was out in the market) * look into the factors that can cause ILD in new users of palbo...
What is the current status of trial NCT07096024?
This trial is currently completed. The enrollment target is 1,772 participants. The study started on 2025-01-21. Estimated completion is 2025-02-07.
What conditions does trial NCT07096024 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT07096024?
The interventions under investigation include: fulvestrant (DRUG), palbociclib plus fulvestrant (DRUG).
Who is sponsoring clinical trial NCT07096024?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07096024 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07096024's enrollment target sits among peer trials
1,772 6th of 97 higher than 92 of 97 other Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Registry Study of Breast Microseed Treatment
RECRUITING
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03067181 · 1,780 participants · Phase 3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- NCT06526650 · 1,780 participants · NA
'Ai Pono Cooking Demonstrations
- NCT06239688 · 1,764 participants · NA
Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce
- NCT05770570 · 1,785 participants · Phase 2
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI